armodafinil
Adjunctive therapy • Brands: Nuvigil
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Nuvigil
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Wakefulness-promoting agent (R-enantiomer of modafinil) indicated for excessive sleepiness in narcolepsy, obstructive sleep apnea (as adjunct to primary therapy), and shift work disorder; Schedule IV with clinically important rash/hypersensitivity warnings and CYP-mediated interaction potential.
Metabolism & Half‑life
- Metabolism: CYP3A4, CYP2C19
- Half‑life: Steady-state mean 15 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- NUVIGIL (armodafinil) tablets prescribing information — DailyMed (2025)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment — Journal of Clinical Sleep Medicine (2021)
- The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy — Current Medical Research and Opinion (2006)